European Open Cable Steady Ahead of BOE German IFO Up Next
All eyes on the FTSE and British pound today as we find out if the BOE will bow to ‘inflationary pressures’ and taper some more.
Share this:
CSL is renowned as a quality company, however, unlike the broader market, its share price is trading about 20% below its 2020 high of $342.75. The source of this underperformance is a sequence of negative developments and a lack of positive catalysts to help the share price recover lost ground.
Learn how to trade shares here
CSL’s plasma collection operations have been hampered by Covid-19 restrictions, limiting its ability to collect plasma. Plasma is an essential ingredient in some of CSL’s immunoglobulin therapies which account for almost half of CSL’s sales. The company is continuing to work on ways to mitigate this issue.
The Covid-19 vaccine CSL was working on with the University of Queensland was scrapped in December after it delivered misleading results regarding HIV diagnoses in trials. Despite signing contracts to produce other vaccines including 51 million doses of AstraZeneca’s vaccine, CSL does not expect the production of vaccines to see a material lift in revenues.
Finally, the company is faced by the headwind of a rising AUD/USD, as a significant portion of its revenues are earned offshore in US dollars.
At its Annual General Meeting in December, CSL said it expects NPAT to grow at between US$2.17 billion to $2.265 billion implying growth of between 3% and 8%. Not overly exciting for a company trading on a price/earnings ratio of more than 40.
Technically, the decline from the $342.75 high of February 2020 appears to be countertrend after a stunning multi-year rally. Once the correction is complete, the uptrend is expected to resume.
As such, we would consider buying a dip into support offered by the trend channel and the March low, $250/240 area. Keeping in mind, a sustained break above trend channel resistance $315 area, would be confirmation the uptrend has resumed.
Source Tradingview. The figures stated areas of the 5th of February 2021. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation
Related tags:
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
Dow Jones forecast: Stock markets under pressure from multiple sources
When looking at the major tech-heavy US indices like the S&P 500 or the Nasdaq 100, you wouldn’t think that the stock market is particularly weak. Yet, beneath the surface, the market is far from healthy right now. Investors are evidently just piling into the big tech and AI names, and as a result, market breadth is deteriorating. Other indices like the small cap Russell 2000 and the Dow Jones are starting to reflect that weakness.
Nikkei breakout accelerates as yen weakness returns
Nikkei has started October with a powerful breakout, helped by renewed yen weakness and strong upside momentum
S&P 500 Forecast: SPX Continues to Drift Away from Record Highs
Recent trading sessions have done little to restore confidence in the equity market. Over the last four sessions, the S&P 500 has declined by nearly 1.00%, a move that highlights growing short-term weakness and keeps the index moving further away from its record-high territory.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.